A Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma

This study is testing whether a new drug called HSK47977 is safe and effective for patients with relapsed or refractory non-Hodgkin's lymphoma — a cancer of the lymphatic system that has come back or stopped responding to previous treatment. **You may be eligible if...** - You are 18 or older - You have been confirmed by biopsy to have relapsed or refractory non-Hodgkin's lymphoma - Your general health is rated 0–2 on the ECOG scale (able to carry out most daily activities) - You are expected to survive at least 3 months - You have at least one measurable tumor on imaging - You are willing to provide a biopsy sample - You agree to use effective contraception during the study and 3 months afterward **You may NOT be eligible if...** - You have another serious uncontrolled medical condition - Your organ function does not meet the study's requirements - You are pregnant or planning to become pregnant during the study Talk to your doctor to see if this trial is right for you.